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ABSTRACT
Venous thromboembolism, including pulmonary embolism 
and deep vein thrombosis, is a signiﬁ cant factor in morbidity 
and mortality of patients. New oral anticoagulants, such as 
apixaban, dabigatran, and rivaroxaban, have recently demon-
strated their safety and eﬃ  cacy in patients undergoing major 
orthopaedic surgery. Selection of the appropriate drug should 
be adjusted according to patient needs. Major bleeding is rare 
with new oral anticoagulants and is comparable with the bleed-
ing rate associated with low-molecular-weight heparins. Clini-
cal data indicate that therapy with apixaban and rivaroxaban 
was more eﬀ ective compared to enoxaparin, while dabigatran 
has a similar eﬃ  cacy to enoxaparin. Cost-eﬀ ectiveness studies 
of new oral anticoagulants showed that these medicines oﬀ er 
higher eﬃ  cacy with acceptable costs for the healthcare system, 
even saving costs in certain cases. Clinical practice in Serbia re-
ﬂ ects considerably more frequent use of traditional anticoagu-
lant medication therapy compared to new oral anticoagulants.
Keywords: new oral anticoagulant, orthopaedic surgery, 
clinical outcomes, economic outcomes
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SAŽETAK
Venska tromboembolija, koja uključuje plućnu em-
boliju i duboku vensku trombozu, predstavlja značajan 
faktor morbiditeta i mortaliteta pacijenata. Novi oralni 
antikoagulansi, poput apiksabana, dabigatrana i rivarok-
sabana, su nedavno pokazali svoju bezbednost i eﬁ kasnost 
kod pacijenata koji se podvrgavaju velikim ortopedskim 
intervencijama. Izbor odgovarajućeg leka treba prilagoditi 
individualnim potrebama pacijenta. Velika krvarenja su 
relativno retka u toku primene novih oralnih antikoagula-
nasa i uporedivi su sa stopom krvarenja prilikom prime-
ne nisko-molekularnih heparina. Klinički podaci ukazuju 
da je terapija apiksabanom i rivarokabanom eﬁ kasnija u 
odnosu na enoksaparin, dok dabigatran ima slične efekte 
kao enoksaparin. Troškovna isplativost novih oralnih an-
tikoagulanasa potvrđuje veću eﬁ kasnost sa prihvatljivim 
troškovima za zdravstveni sistem, u nekim slučajevima 
čak i sa uštedama.
Ključne reči: novi oralni antikoagulansi, ortopedska hi-
rurgija, klinički ishodi, ekonomski ishodi
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INTRODUCTION
Venous thromboembolism (VTE), which includes pul-
monary embolism (PE) and deep vein thrombosis (DVT), is a 
significant factor in morbidity and mortality of patients. The 
incidence of VTE in the world is approximately 1 person per 
1,000 in one year, while 180 000 deaths are annually recorded 
in the United States as a result of VTE (1-3). In Europe, 1.66 
million cases of non-fatal symptomatic VTE are recorded 
per year (4). In the majority of hospitalized patients, clot pre-
disposing factors are present, especially in orthopaedic and 
surgical patients. High risk of VTE is present in patients who 
are undergoing knee and/or hip surgery. According to clinical 
studies, the percentage of venography that confirmed DVT in 
major joint surgery without the use of prophylaxis is between 
40% and 85% (5, 6). Therefore, pharmacological prophylaxis 
represents a very important factor in the reduction of mor-
bidity and mortality in patients who are undergoing major 
orthopaedics surgeries. For many years, warfarin and low-
molecular-weight heparins were applied with prophylactic 
purposes. However, all of these drugs have certain limitations 
in modern clinical practice (7). In the last several years, sever-
al new oral anticoagulants were approved for the prevention 
of VTE in these patients (8).
4CLINICAL OUTCOMES OF NEW ORAL ANTICO-
AGULANTS
New oral anticoagulants (NOA), such as apixaban, dab-
igatran, and rivaroxaban, have recently demonstrated their 
safety and efficacy. These NOAs are currently considered 
to be an alternative to warfarin. The new oral anticoagu-
lants have a predictable and stable pharmacokinetics with 
low potential for interaction. These medicines do not need 
continuous monitoring or frequent adjustment of dose, 
and there is a low probability that they will cause intracra-
nial bleeding (8). The development of NOA that is used in 
orthopaedic surgery has great clinical significance.
Apixaban
Apixaban is a direct and reversible factor Xa inhibitor 
(9). Studies for the prevention of DVT in animal models 
showed that apixaban has adequate efficiency. The recom-
mended daily dose is 2.5 mg orally twice daily. To minimize 
undesirable outcomes, the starting dose should be initiated 
12-24 h after the surgery (10). Apixaban has good bioavail-
ability, low clearance and low potential for interactions 
with other drugs and is eliminated by urine, bile and faeces 
(11). In 2011, apixaban was approved in Europe for pre-
vention of DVT in patients who had elective hip or knee 
replacement surgery. For this indication, apixaban is avail-
able in more than 50 countries (12). Use of apixaban in the 
prevention of DVT is supported by 3 clinical trials, known 
as the ADVANCE clinical studies (13-15). The studies were 
designed to assess the safety and efficacy of apixaban in 
more than 11,500 patients, of which 5770 patients were on 
apixaban and 5,755 patients were on enoxaparin. 
ADVANCE-1 (13) and ADVANCE-2 (14) studies have 
evaluated the use of apixaban in patients who underwent 
elective knee replacement surgery, while the ADVANCE-3 
study (15) evaluated the effects in patients who under-
went elective hip replacement surgery. During Phase III 
in all three ADVANCE studies, the primary efficacy end-
point composed of all VTE and all-cause mortality were 
followed, while for the safety assessment, the occurrence 
of bleeding during treatment was followed. Apixaban 
showed a statistically superior reduction in the primary 
endpoint compared to enoxaparin in both elective hip or 
knee replacement surgery. The risk of major bleeding after 
administration of apixaban was significantly lower com-
pared to enoxaparin (OR = 0.55; 95% CI 0.32, 0.96) (16). 
Apixaban parameters of efficacy and safety compared to 
warfarin have been published in 2012, and these results are 
even more convincing compared to enoxaparin. Incidence 
of VTE and all-cause mortality were 9% in the apixaban 
group compared to 26.6% in the warfarin group. The in-
cidence of bleeding was comparable between groups (17).
Dabigatran
Dabigatran is a direct thrombin inhibitor, which conse-
quently results in antiplatelet activity. Dabigatran is indi-
cated for the primary prevention of VTE in adult patients 
undergoing elective total hip or knee replacement surgery. 
Key studies have shown that dabigatran has similar ef-
ficacy and safety as enoxaparin. Compared to vitamin K 
antagonists (warfarin), dabigatran provides a number of 
advantages, including the lack of interaction with food, 
oral administration, no risk of thrombocytopenia and a 
predictable anticoagulant effect. Dabigatran clinical trials 
in the US and Europe estimated its importance for preven-
tion of thromboembolic events. In 2008, dabigatran was 
approved by the EMA for the primary prevention of VTE 
in patients who underwent total hip or knee replacement 
(18). The results of post-marketing studies (RE-study) ad-
ditionally confirmed the validity of dabigatran use in pre-
vention of VTE in orthopaedic patients compared to low-
molecular-weight heparin (19).
Later meta-analysis of the RE-MODEL, RE-NOVATE 
and RE-MOBILIZE studies showed that there were no 
significant differences in efficacy between dabigatran and 
enoxaparin, including the total VTE and mortality (20).
The latest study from 2015 estimated the safety and 
efficacy of dabigatran for the prevention of VTE in pa-
tients undergoing total hip or knee replacement, but for 
those previously treated with low-molecular-weight hepa-
rins. The authors concluded that switching patients from 
low-molecular-weight heparin to dabigatran is a safe and 
effective pharmacotherapy. In addition, switching from 
a subcutaneous to an oral therapy offered an easier, less 
expensive, and more convenient route of administration 
for the patients and healthcare professionals (21). As with 
the other NOA, the major concerns regarding the safety 
profile are the frequency and severity of bleeding. In all of 
the abovementioned studies, the safety of dabigatran was 
comparable to that of the low-molecular-weight heparins. 
In the RE-studies, a similar safety profile of dabigatran 
and warfarin for risk of major bleeding was observed. The 
incidence of relevant bleeding, especially cerebral bleed-
ing, was low in patients who were treated with dabigatran 
compared to other anticoagulants in the Phase III study. 
This supports once more a desirable safety profile of dabi-
gatran (22). 
Rivaroxaban
Rivaroxaban is a direct and selective factor Xa inhibi-
tor (23). Rivaroxaban is approved in the United States and 
the European Union for the prevention of VTE in patients 
undergoing a total hip or knee replacement (24). In four 
RECORD studies, which included more than 12,500 pa-
tients, the efficacy of rivaroxaban was superior compared 
to enoxaparin in major orthopaedic surgery (25-28). The 
incidence of DVT and non-fatal PE was significantly low-
er in the rivaroxaban group compared to the enoxaparin 
group, regardless of whether it was an elective knee (30% 
to 50% reduction in incidence of VTE) or hip surgery (de-
creased for more than 70%). In addition, the safety profiles 
of these drugs were very similar. The latest international 
study XAMOS (Xarelto®, use in prophylaxis of surgical ve-
nous thromboembolism after major orthopaedic surgery 
5of the hip or knee) intended to provide additional infor-
mation on the assessment of the benefits and risks of use 
of rivaroxaban compared with standard VTE prophylaxis. 
More than 17,000 patients from 37 countries participated 
in this study between February 2009 and August 2011. Ri-
varoxaban was associated with a significantly lower rate of 
thromboembolic events. The relevant bleeding rate was 
similar between the two groups. Therefore, it was conclud-
ed that the non-intervention study XAMOS confirmed the 
results of the RECORD clinical trial (29).
ECONOMIC OUTCOMES OF NEW ORAL ANTI-
COAGULANTS
The cost-effectiveness of therapy certainly plays an 
important role in the selection of an appropriate antico-
agulant drug. There is a continued need for saving time 
and money in addition to maintaining the simplicity of the 
drug application. Use of aspirin, due to its low price and 
simple administration, is shown to be a good alternative 
to low-molecular-weight heparins after hip or knee sur-
gery (30). New oral anticoagulants play a significant role 
in reducing cost when compared to low-molecular-weight 
heparins (31).
Apixaban
A Canadian study analysed the cost-effectiveness of 
apixaban compared to enoxaparin in prophylactic therapy 
for DVT in patients undergoing total hip or knee replace-
ment. In the study, two economic models, decision tree 
and Markov model, were combined. The results showed 
that apixaban was better (more effective and less expen-
sive) than enoxaparin in treating patients undergoing ma-
jor orthopaedic surgery. Savings of USD180 to USD270 
per patient could be expected with apixaban treatment 
compared to enoxaparin treatment (32). Budgetary impact 
for the Spanish health system of apixaban prophylaxis of 
VTE in patients undergoing total knee or hip replacement 
showed that the inclusion of apixaban did not have any 
positive monetary impact, but led to a reduction in the rate 
of VTE and bleeding (33). In the British guidance of apixa-
ban, it is stated that apixaban was more clinically effective 
and less expensive than enoxaparin; however, it was also 
concluded that there was insufficient clinical evidence to 
determine whether apixaban was more or less clinically ef-
fective than another NOA (34).
Dabigatran 
For in- or out-patients in need for thromboprophylaxis 
after orthopaedic surgery, the total cost of enoxaparin ad-
ministration becomes higher than that of dabigatran, mak-
ing dabigatran therapy cost-effective for these groups of 
patients (22). The British guidance from 2008 concluded 
that dabigatran was likely to be of equivalent clinical and 
cost effectiveness to low-molecular-weight heparins for 
the prevention of VTE but had advantages in route of ad-
ministration since it did not have a need for monitoring, 
and demonstrated a reduction in administration costs and 
better adherence to treatment (35).
Rivaroxaban
The cost-effectiveness of rivaroxaban was assessed in 
several countries based on the data from the RECORD 
studies. In the Germany study, prophylaxis with rivar-
oxaban reduced the number of VTE events and provided 
cost savings (EUR27.3 saving per patient treated) com-
pared with enoxaparin (36). A cost-effectiveness study 
conducted for the Swedish health system showed that in 
patients undergoing total hip replacement, the extended 
prophylaxis for 35 days with rivaroxaban was cost-effec-
tive compared to 14 days of prophylaxis with enoxaparin 
or dalteparin. In total knee replacement patients, 14 days 
of rivaroxaban treatment was more effective and less ex-
pensive than 14 days of low-molecular-weight heparin 
prophylaxis for VTE (37).
CLINICAL PRACTICE IN SERBIA
Despite the availability of NOA, the dominant place in 
clinical practice in Serbia still use low-molecular-weight 
heparins and older anticoagulants, such as warfarin or 
acenocoumarol. The main reason for this is the limited 
availability of NOA in Serbia. Although all three NOAs 
have marketing authorization in Serbia, only dabigatran 
and rivaroxaban are on the reimbursement list (38). The 
supply of these two drugs is based on a centralized public 
procurement procedure.
Table 1 shows the IMS (IMS Health, IMS Health Da-
tabase) consumption data of pharmacological agents that 
are used in the prophylaxis of VTE during the four-year 
period (2012-2015). All data are presented according to the 
original packaging. A low-molecular-weight heparin, nad-
roparin, had the highest consumption over all four years.
Figure 1 shows the consumption of drugs used in the 
prophylaxis of VTE according to the WHO/DDD method-
ology. The defined daily dose (DDD) is a unit of measure-
ment that was proposed by the World Health Organization 
(WHO). DDD is defined as “the assumed average main-
tenance dose per day for a drug used for its main indica-
tion in adults.” Unit DDD represents the average dose for 
an adult weighing 70 kg in primary indication of the ATC 
classification system. This dose is independent from the 
price of the pharmaceutical form, while the concentration 
is in a single form and size of the package (39). The number 
of inhabitants each year is taken from the website of the 
Republic Institute for Statistics (40).
The highest consumption of pharmacotherapy for pro-
phylaxis of VTE was recorded during 2015 with a total 
8.21 DDD/1000 inhabitants/day. During the four years, 
the largest share in the consumption belonged to warfarin 
(41% in 2014; 58% in 2013). During the observed period, 
NOA consumption growth was recorded.
6Table 2 shows the volume of drugs used in the preven-
tion of VTE, which was obtained through public procure-
ment. The table shows data on an annual basis for 2014 
and adjusted data for 2015, considering the different time 
durations of public procurement.
CONCLUSIONS
In the future, an increase in the number of hip and knee 
operations is expected. For this reason, safe and effective 
prophylaxis is essential to reduce mortality and morbidity 
related to VTE. The NOAs have the potential to reduce 
the incidence of VTE after total hip and knee replacement. 
Therefore, NOAs can contribute to significant savings 
through the reduction of VTE rate, improved safety and 
reduced costs of monitoring and administration.
Implementation of NOAs in prophylaxis of VTE is 
easy and straightforward, but there are specific pharma-
cological differences between apixaban, rivaroxaban and 
dabigatran. Selection of the appropriate drug should be 
adjusted according to the patient needs. Major bleed-
ing is rare with NOA and comparable with the bleed-
ing rate with low-molecular-weight heparins. All NOAs 
have predictable pharmacokinetics with a short half-life. 
Clinical data indicate that therapy with apixaban and ri-
varoxaban was more effective compared to enoxaparin, 
while dabigatran has a similar efficacy to that of enoxa-
parin. Cost-effectiveness studies of NOAs showed that 
these medicines offer higher efficacy with acceptable 
INN Package, pharmaceutical form, strength 2012 2013 2014 2015
warfarin 30 tablets, 5 mg 372,867 404,686 325,543 461,714
acenocoumarol 20 tablets, 4 mg 134,614 103 163,665 253,596
heparin 5 ampules, 5000IU/0.25 ml 36,154 35,315 4,850 7
heparin 5 ampules, 5000IU/ml 28,849 34,158 35,743 46,633
heparin 10 ampules, 25000IU/5 ml 27,828 34,890 32,510 31,638
dalteparin 10 preﬁ lled syr., 2500IU/0.2 ml 15,831 19,168 13,550 13,880
dalteparin 10 preﬁ lled syr., 5000IU/0.2 ml 15,061 12,834 14,478 10,660
dalteparin 10 preﬁ lled syr., 10000IU/ml 60 74 50
enoxaparin 2 preﬁ lled syr., 2000IU/0.2 ml 24,552 27,528 4,048 27
enoxaparin 10 preﬁ lled syr., 2000IU/0.2 ml 3 3,499 3,679
enoxaparin 2 preﬁ lled syr., 4000IU/0.4 ml 103,176 117,359 10,162 3
enoxaparin 10 preﬁ lled syr., 4000IU/0.4 ml 807 23,925 27,017
enoxaparin 2 preﬁ lled syr., 6000IU/0.6 ml 72,912 84,697 5,621
enoxaparin 10 preﬁ lled syr., 6000IU/0.6 ml 548 18,659 20,696
enoxaparin 2 preﬁ lled syr., 8000IU/0.8 ml 47,661 55,532 989 1
enoxaparin 10 preﬁ lled syr., 8000IU/0.8 ml 402 9,766 10,455
nadroparin 10 preﬁ lled syr., 2850IU/0.3 ml 118,549 131,788 156,425 161,072
nadroparin 10 preﬁ lled syr., 3800IU/0.4 ml 20,050 26,674 30,968 42,319
nadroparin 10 preﬁ lled syr., 5700IU/0.6 ml 41,299 52,753 64,467 73,911
reviparin 10 preﬁ lled syr., 1750IU/0.25 ml 1.407
reviparin 10 preﬁ lled syr., 3436IU/0.6 ml 1,463
fondaparinux 10 preﬁ lled syr., 2.5 mg/0.5 ml 883 1,460 1,036 1,370
rivoroxaban 10 tablets, 10 mg 95 860 1,944 2,577
rivoroxaban 28 tablets, 15 mg 48 1,153 4,357
rivoroxaban 42 tablets, 15 mg 13 76 64
rivoroxaban 28 tablets, 20 mg 189 2,942 8,798
dabigatran 10 capsules, 110 mg 102 101 296 236
dabigatran 30 capsules, 75 mg 131 243 356 357
dabigatran 10 capsules, 75 mg 40 254 354 379
dabigatran 30 capsules, 110 mg 93 254 225 316
dabigatran 60 capsules, 150 mg 493 4,032 9,610
dabigatran 60 capsules, 110 mg 662 5,053 12,235
Table 1. Consumption of drugs used in the prophylaxis of VTE during the period 2012 - 2015 (IMS Health Database)
7Table 2. Consumption of drugs used in the prophylaxis of VTE through centralized public procurement in 2014 and 2015
* - Refers to the original packaging and not to individual forms (tablet)
INN Pharmaceutical form, strength Number of unit doses 
in 2014
Number of unit doses 
in 2015
warfarin 30 tablets, 5 mg (original pack) 140,000*
acenocoumarol 20 tablets, 4 mg (original pack) 45,250*
heparin ampule, 5000IU/0.25 ml 140,600 74,666
heparin ampule, 5000IU/1 ml 99,500 111,376
heparin ampule, 25000IU/5 ml 146,800 253,960
dalteparin preﬁ lled syr., 2500IU/0.2 ml 119,400 200,464
dalteparin preﬁ lled syr., 5000IU/0.2 ml 95,600 223,664
dalteparin preﬁ lled syr., 10000IU/ml 1,000 104
enoxaparin preﬁ lled syr., 2000IU/0.2 ml 32,700 25,096
enoxaparin preﬁ lled syr., 4000IU/0.4 ml 154,900 160,000
enoxaparin preﬁ lled syr., 6000IU/0.6 ml 115,000 144,512
enoxaparin preﬁ lled syr., 8000IU/0.8 ml 63,600 78,400
nadroparin preﬁ lled syr., 2850IU/0.3 ml 897,000 1,160,808
nadroparin preﬁ lled syr., 3800IU/0.4 ml 139,000 229,784
nadroparin preﬁ lled syr., 5700IU/0.6 ml 287,000 469,776
rivoroxaban tablet, 10 mg 3,000
dabigatran capsule, 75 mg 200
dabigatran capsule, 110 mg 800
Figure 1. Consumption of drugs used in the prophylaxis of VTE according to the WHO/DDD methodology from 2012 to 2015
8costs for healthcare system and, in certain cases, even 
presented with savings. NOAs represent an alternative to 
traditional anticoagulants due to the following advantag-
es: no titration of the dose, low capacity for interactions 
and no need for monitoring. In that line, NOAs are con-
sidered to be effective, acceptable in safety profile and 
a cost-effective alternative to parenteral pharmacologi-
cal prophylaxis. Clinical practice in Serbia reflects con-
siderably more frequent use of traditional anticoagulant 
medication therapy compared to NOA.
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